Revolutionary Universal Vaccine Candidate Enters Phase 3 European Clinical Trials

Broadly neutralizing antibody therapy demonstrates 98% efficacy against seasonal viral variants.

This is the full reporting content for Revolutionary Universal Vaccine Candidate Enters Phase 3 European Clinical Trials, published by The 24 European News editorial team. Coverage includes complete background analysis, expert insights, and live developments.